← All diseases Cancer

Multiple myeloma

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest level of evidence only (64)Meta-analysis (11)Treatment guideline (2)Systematic review (24)Randomized trial (16)Phase 3 study (11)Clinical trial (628)Review article (259)Early study (phase 1 or 2) (44)Case report (253)Laboratory or animal study (23)Commentary or editorial (45)Retracted Publication (4)Concerns have been raised (1) Studies currently recruiting participants only (46)

Filter

Publications (1566)

• Geriatric nutritional risk index predicts 10-year survival in patients with multiple myeloma. (2026/07/06) ♡
• Functional motif detection via in silico ablation using AlphaGenome. (2026/07/03) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Multiple Myeloma and the Illusion of the Evidence Pyramid. (2026/07/02) ♡
• Is it Necessary to Achieve a Very Good Partial Response Prior to Transplant? Comparison of Outcomes in Pre-Transplant Partial Response Versus Very Good Partial Response or Deeper. (2026/07/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Complete Response to Teclistamab in a Pentarefractory Elderly Patient with Multiple Myeloma: A Real-World Case Report from India. (2026/07/01) ♡
• Plasma Cell Morphology: Many Faces, One Essence. (2026/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives. (2026/07/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction. (2026/07/01) ♡
• Engineering Soluble Recombinant BCMA for Ide-Cel Labeling. (2026/07/01) ♡
• Monoclonal Gammopathies in Kidney Transplant Recipients: A Retrospective Analysis of Incidence, Clinical Characteristics, and Outcomes. (2026/07/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. When "Metastatic Disease" Is Not Metastatic: Diffuse Large B-cell Lymphoma Presenting With a Perisplenic Mass, Pulmonary Masses, Pleural Effusion, and Retroperitoneal Lymphadenopathy. (2026/06/30) ♡
• Clinical Outcomes of Acute Pancreatitis in Patients With Multiple Myeloma. (2026/06/29) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. 3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells. (2026/06/25) ♡
• Breaking the Balance: Baseline Oxidative Stress and DNA Repair Capacity in Multiple Myeloma Therapy. (2026/06/19) ♡
• Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept. (2026/06/17) ♡
• Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status. (2026/06/15) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Severe plaque psoriasis exacerbation during lenalidomide maintenance after autologous stem cell transplantation for multiple myeloma. (2026/06/13) ♡
• Nutritional status, dietary antioxidant capacity, and dietary diversity in patients with newly diagnosed hematological malignancies: a case-control study. (2026/06/02) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM. (2026/06/01) ♡
• Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans. (2026/06/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study. (2026/06/01) ♡
• Impact of pretransplant CONUT score on posttransplant engraftment kinetics and overall survival in patients with multiple myeloma. (2026/06/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity. (2026/06/01) ♡
• [Correlation of CD269 Expression Patterns with Antigen Expression and Molecular Cytogenetics Abnormalities in Patients with Multiple Myeloma]. (2026/06/01) ♡
• [Multi Model Study and Clinical Decision Analysis of Early Death Risk Warning in Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab]. (2026/06/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [The Clinical Significance and in vitro Experimental Study of hnRNP U in Multiple Myeloma]. (2026/06/01) ♡
• [Analysis of Clinical Features of Newly Diagnosed Multiple Myeloma Complicated with Light Chain Amyloidosis]. (2026/06/01) ♡
• [Validation of the Predictive Ability of IMWG, IMPEDE and SAVED Thrombosis Risk Stratification Systems for Venous Thromboembolism in Chinese Multiple Myeloma Patients]. (2026/06/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Cancer Therapy Using Antiparasitic Medications Guided by Acupuncture Meridian Assessment: A Case Series of Six Patients. (2026/06/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Body mass index and multiple myeloma: a systematic review and dose-response meta-analysis of prospective cohort studies. (2026/05/28) ♡
• Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma. (2026/05/28) ♡
• European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B-Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community-Based Centers and for Outpatient Step-Up Dosing. (2026/05/14) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Leveraging Dietary Interventions to Benefit Patients with Hematologic Malignancies and Clonal Hematopoiesis. (2026/05/14) ♡
• Diet and risk of multiple myeloma: findings from a case-control study. (2026/05/13) ♡
• Dynamic HALP Score as a Time-Dependent Prognostic Biomarker in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. (2026/05/12) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Olmesartan-Induced Enteropathy Mimicking Amyloidosis in the Setting of New Multiple Myeloma Diagnosis. (2026/05/12) ♡
• Circulating levels of insulin-like growth factor binding protein 7 are associated with risks of chronic diseases and death. (2026/05/09) ♡
• Dysplastic plasma cells in multiple myeloma. (2026/05/01) ♡
• Is Consolidation Therapy Effective in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Single Center Real-Life Data with Cyclophosphamide-Bortezomib-Dexamethasone or Bortezomib-Lenalidomide-Dexamethasone? (2026/05/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Pancreatic Plasmacytoma Post-Allogeneic-HSCT: Diagnosis by EUS-Guided Biopsy. (2026/05/01) ♡
• Vitamin D status and chemotherapy-induced peripheral neuropathy: A scoping review. (2026/05/01) ♡
• Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations. (2026/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report. (2026/05/01) ♡
• Coumarin- and Dipicolylamine-Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer Potential. (2026/04/30) ♡
• Single-cell RNA sequencing analysis revealed a potential association between ELK3 expression and the progression of multiple myeloma. (2026/04/20) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. (2026/04/18) ♡
• Association between healthy lifestyle score and risk of multiple myeloma: a case-control study. (2026/04/15) ♡
• Dietary intake and the risk of monoclonal gammopathy of undetermined significance: results from the population-based iStopMM screening study. (2026/04/08) ♡
• Nutritional vulnerability, food insecurity, and unmet supportive care needs in multiple myeloma: a cross-sectional study from China. (2026/04/08) ♡
• Microenvironmentally derived fatty acid-binding proteins 4 and 5 are novel therapeutic vulnerabilities in multiple myeloma. (2026/04/02) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.